HomeCompareFRTAY vs ABBV

FRTAY vs ABBV: Dividend Comparison 2026

FRTAY yields 7.31% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRTAY wins by $58191.32M in total portfolio value
10 years
FRTAY
FRTAY
● Live price
7.31%
Share price
$15.01
Annual div
$1.10
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$58191.43M
Annual income
$56,700,628,091.33
Full FRTAY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FRTAY vs ABBV

📍 FRTAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRTAYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRTAY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRTAY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRTAY
Annual income on $10K today (after 15% tax)
$621.05/yr
After 10yr DRIP, annual income (after tax)
$48,195,533,877.63/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FRTAY beats the other by $48,195,512,821.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRTAY + ABBV for your $10,000?

FRTAY: 50%ABBV: 50%
100% ABBV50/50100% FRTAY
Portfolio after 10yr
$29095.76M
Annual income
$28,350,326,431.54/yr
Blended yield
97.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FRTAY
No analyst data
Altman Z
2.9
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRTAY buys
0
ABBV buys
0
No recent congressional trades found for FRTAY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRTAYABBV
Forward yield7.31%3.06%
Annual dividend / share$1.10$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$58191.43M$102.3K
Annual income after 10y$56,700,628,091.33$24,771.77
Total dividends collected$58089.22M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FRTAY vs ABBV ($10,000, DRIP)

YearFRTAY PortfolioFRTAY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,161$1,461.29$11,550$430.00+$611.00FRTAY
2$16,334$3,321.72$13,472$627.96+$2.9KFRTAY
3$25,817$8,339.31$15,906$926.08+$9.9KFRTAY
4$52,261$24,636.66$19,071$1,382.55+$33.2KFRTAY
5$149,137$93,217.76$23,302$2,095.81+$125.8KFRTAY
6$656,802$497,225.40$29,150$3,237.93+$627.7KFRTAY
7$4,795,845$4,093,066.82$37,536$5,121.41+$4.76MFRTAY
8$60,994,752$55,863,198.07$50,079$8,338.38+$60.94MFRTAY
9$1,393,268,316$1,328,003,931.37$69,753$14,065.80+$1393.20MFRTAY
10$58,191,425,189$56,700,628,091.33$102,337$24,771.77+$58191.32MFRTAY

FRTAY vs ABBV: Complete Analysis 2026

FRTAYStock

freenet AG provides telecommunications, radio and multimedia, mobile communications, mobile Internet, and digital lifestyle services in Germany. It provides a portfolio of services and products primarily in the areas of mobile voice and data services. The Mobile Communications segment offers mobile communications services, such as marketing of mobile communications services, which include voice and data services from the mobile communications network operators; sells and distributes mobile communications devices, as well as offers additional services for mobile data communications and digital lifestyle; and planning, construction, installation, and maintenance services for WiFi networks. The TV and Media segment provides services to end users in the field of DVB-T2 and IPTV; and planning, project management, installation, operation, service, and marketing services for broadcast-related solutions for business clients in the radio and media sectors. The Other/Holding segment offers portal services, such as e-commerce/advertising services; payment services; various digital products and entertainment formats for downloading and displaying, as well as use on mobile devices; communication development solutions, IT solutions, and other services; and voice and data services. The company provides its services under the mobilcom debitel, GRAVIS, MEDIA BROADCAST, klarmobile.de, freenet ENERGY, vitrado.de, FUNK, freenet BASICS, freenet MOBILE, freenet VIDEO, freenet.de, freenet FLEX, freenet TV, waipu.tv, CARMADA, The Cloud, and freenet Business brands. It operates approximately 520 mobilcom-debitel shops and 40 GRAVIS stores. The company sells its products through approximately 400 electronics stores, as well as online platforms. freenet AG was founded in 2005 and is headquartered in Büdelsdorf, Germany.

Full FRTAY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FRTAY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRTAY vs SCHDFRTAY vs JEPIFRTAY vs OFRTAY vs KOFRTAY vs MAINFRTAY vs JNJFRTAY vs MRKFRTAY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.